Shire’s Vyvanse Getting Increased Attention From ADHD Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Attention deficit/hyperactivity disorder drug gained a 2.8 percent share of the market two months after its launch, Shire reports.
You may also be interested in...
FDA Approves Shire’s Once-daily Vyvanse For Adult ADHD
British biopharma had pegged nearly one-third of drug’s sales to off-label adult usage.
FDA Approves Shire’s Once-daily Vyvanse For Adult ADHD
British biopharma had pegged nearly one-third of drug’s sales to off-label adult usage.
Shire Submits Vyvanse sNDA For Adult ADHD
The company plans to announce data from a Phase III trial in adults in the fourth quarter.